Heska (NASDAQ: HSKA – Get a rating) saw its price target raised by equity researchers at Alliance Global Partners from $150.00 to $155.00 in a report on Thursday, Fly reports. Alliance Global Partners’ price target indicates a potential upside of 55.48% from the company’s current price.
Other research analysts have also published reports on the company. Piper Sandler cut her price target on Heska from $190.00 to $180.00 and gave the stock a “na” rating in a research report on Sunday. StockNews.com began covering Heska in a research report on Thursday, March 31. They issued a “holding” rating on the stock. Zacks Investment Research downgraded Heska from a “hold” rating to a “strong sell” rating in a Tuesday, March 8 research report. Morgan Stanley cut its price target on Heska from $190.00 to $161.00 and set an “equal weight” rating on the stock in a Tuesday, March 1 research report. Finally, TheStreet downgraded Heska from a “c-” rating to a “d+” rating in a Friday, February 11 research report. One research analyst rated the stock with a sell rating, two assigned a hold rating and three assigned the company a buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $219.83.
HSKA Share traded at $3.72 in midday trading on Thursday, reaching $99.69. 430 shares of the company have been traded in the hands, compared to its average volume of 97,463. The company has a 50-day simple moving average of $127.00 and a two-hundred-day simple moving average of 147.45 $. Heska has a 1-year minimum of $82.92 and a 1-year maximum of $275.94. The company has a market capitalization of $1.08 billion, a price-earnings ratio of -78.80 and a beta of 1.64. The company has a quick ratio of 5.37, a current ratio of 6.73 and a debt ratio of 0.23.
Heska (NASDAQ: HSKA – Get a rating) last reported quarterly earnings data on Monday, May 9. The medical research company reported EPS of $0.27 for the quarter, beating consensus analyst estimates of $0.11 from $0.16. The company posted revenue of $64.80 million for the quarter, versus analyst estimates of $66.32 million. Heska had a negative return on equity of 0.95% and a negative net margin of 5.04%. The company’s quarterly revenue increased by 7.1% compared to the same quarter last year. During the same period last year, the company achieved EPS of $0.20. Equity research analysts expect Heska to post an EPS of 0.43 for the current year.
A number of institutional investors have recently changed their holdings in HSKA. Allspring Global Investments Holdings LLC acquired a new stake in Heska stock in Q4 valued at approximately $63,789,000. abrdn plc increased its stake in Heska shares to 99.7% in Q4. abrdn plc now owns 327,820 shares of the medical research company valued at $59,824,000 after buying an additional 163,689 shares during the period. Manning & Napier Group LLC increased its stake in Heska shares by 164.8% in Q1. Manning & Napier Group LLC now owns 181,566 shares of the medical research company valued at $25,105,000 after purchasing an additional 112,997 shares during the period. Millennium Management LLC increased its stake in Heska shares to 82.3% in Q4. Millennium Management LLC now owns 151,893 shares of the medical research company valued at $27,719,000 after purchasing an additional 68,591 shares during the period. Finally, BlackRock Inc. increased its stake in Heska shares by 3.0% in the third quarter. BlackRock Inc. now owns 1,818,027 shares of the medical research company valued at $470,032,000 after purchasing an additional 53,285 shares during the period. 95.94% of the shares are currently held by institutional investors and hedge funds.
Heska company profile (Get a rating)
Heska Corporation sells veterinary and animal health diagnostic and specialty products for the canine and feline health markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, in Spain and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers for measuring blood cell and platelet counts, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and the Element COAG and Element AIM veterinary analyzers.
Read more
Get news and reviews for Heska Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Heska and related companies with MarketBeat.com’s FREE daily newsletter.
Comments are closed.